About the company
Compugen Ltd is a pioneering biopharmaceutical company that specializes in therapeutic discovery and development. Leveraging their advanced predictive computational discovery capabilities, the company is dedicated to identifying and developing novel drug targets and innovative biological pathways in the field of cancer immunotherapy. The cornerstone of Compugen's immuno-oncology portfolio lies in its four clinical-stage programs. These programs strategically target immune checkpoints that have been discovered computationally, offering immense potential for breakthrough advancements in cancer treatment. One of these programs is COM701, a promising therapeutic candidate that aims to enhance anti-tumor immune responses by targeting the PVRIG and TIGIT immune checkpoints. By specifically targeting these immunosuppressive molecules, COM701 has the potential to overcome immune resistance and significantly improve patient outcomes. Another notable program in Compugen's pipeline is COM902, an innovative therapy targeting the TIM-3 immune checkpoint. TIM-3 plays a vital role in regulating immune responses, and its dysregulation has been linked to immune escape mechanisms in cancer. COM902 has demonstrated promising preclinical results, showcasing its ability to effectively engage TIM-3 and unlock the patient's immune response in the fight against cancer. In addition to these programs, Compugen's immuno-oncology pipeline features bapotulimab, a unique antibody that targets the immune checkpoint known as ILDR2. This program holds significant promise as ILDR2 is an emerging immunotherapeutic target involved in modulating immune responses in multiple cancer types. By effectively inhibiting ILDR2, bapotulimab has the potential to enhance anti-tumor immune activity and offer a new approach to personalized cancer treatment. Apart from their clinical-stage programs, Compugen is actively developing a pipeline of early-stage immuno-oncology programs. These programs aim to address various mechanisms of immune resistance, including targeting myeloid cells. Myeloid cells play a crucial role in tumor growth and immune evasion, making them attractive targets for therapeutic intervention. By strategically targeting myeloid cells, Compugen aims to develop treatments that disrupt the immunosuppressive microenvironment within tumors and enhance the efficacy of existing immunotherapies. Compugen's dedication to leveraging cutting-edge computational discovery tools and their unwavering commitment to cancer immunotherapy puts them at the forefront of the biopharmaceutical industry. With their innovative pipeline and focus on developing novel therapies, Compugen aims to revolutionize cancer treatment and improve the lives of patients worldwide.
Website: https://cgen.com
Data updated: June 2, 2026
